{
  "docId": "019de518-6502-70bc-9a44-c6a9c7f323b5",
  "docSlug": "4230ce80abe7092521a593effe59cbcd",
  "documentTitle": "Oculis | Investor Presentation Deck | 48 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 48,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "other",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de518-6502-70bc-9a44-c6a9c7f323b5/37",
  "deckHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5",
  "deckJsonHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5.json",
  "deckAnchorHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.88,
        "x": 0.07,
        "y": 0.62
      },
      "kind": "diagram",
      "text": "Screening\n2 week run in, all subjects\nArtificial tears TID\nPatients who respond to artificial tears will not be randomized\nRandomization\n6 weeks\nTBD\nOCS-02 3x/day (TID)\nFollow-up\nVehicle (TID)\nFollow-up",
      "attrs": {},
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bd2b324-383e-4873-b11b-1ec63858b626",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.11,
        "x": 0.85,
        "y": 0.04
      },
      "kind": "image",
      "text": "Oculis",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12f86993-8162-475d-bc97-32bda5583b45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.23,
        "w": 0.26,
        "x": 0.04,
        "y": 0.29
      },
      "kind": "list",
      "text": "Phase 2b study design:\nRandomized, masked, vehicle-controlled study\nMulti-center, 10-week, approx. 120 subjects\nStratification based on genotype (CC SNP) 20% patients",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81d68b1e-50df-4704-852b-3549332c2d00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.19,
        "w": 0.3,
        "x": 0.64,
        "y": 0.29
      },
      "kind": "list",
      "text": "Key Enrollment Criteria:\nSubjects with history of DED for 6 months\nSchirmer's test at baseline < 10 mm\nCorneal fluorescein stain ≥ 2 in at least 1 region (inferior, superior)",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "920e883f-25d1-410a-b597-cdac4cec8aef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.26,
        "x": 0.34,
        "y": 0.29
      },
      "kind": "list",
      "text": "Objectives:\nThe objective of this study is to evaluate the efficacy and safety of OCS-02 for the treatment of signs of dry eye disease",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db092064-1727-427c-b9a7-8bae70c3a7e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.76,
        "x": 0.026,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "A multi-center, randomized, double-masked, vehicle-controlled study evaluating the efficacy and safety of OCS-02 for the treatment of signs and symptoms of DED",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce69509f-308c-4f83-b468-2474ec2ede1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.01,
        "w": 0.02,
        "x": 0.95,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "37",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bf73fdc-f442-42ff-81c8-d8e7885ceeb9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.036,
        "w": 0.66,
        "x": 0.026,
        "y": 0.044
      },
      "kind": "title",
      "text": "OCS-02 | Phase 2b Trial in Dry Eye Disease",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21f9ad9c-bead-4520-a59c-8a35daa31f39",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Process flow",
      "slug": "process-flow",
      "agent": null,
      "layer": "slide",
      "matchId": "829c88c7-0632-42a9-b5d6-9c153e9f8455",
      "evidence": "diagram/process: Screening 2 week run in, all subjects Artificial tears TID Patients who respond to artificial tears will not be randomized Randomization 6 weeks TBD OCS-02 3x/day (TID) Follow-up Vehicle (TID) Follow-up",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}